EWTX · CIK 0001710072
What Edgewise Therapeutics, Inc. told the SEC could break it.
2 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
A limited set so far — we surface every cited disclosure we’ve extracted for EWTX. More may follow as additional filings are processed.
In its own words
What could break it.
Regulatory & policy
- China-linked contractor / data-transfer + tariff exposure — FDA/DOJ scrutiny of China-based drug manufacturers & sensitive-data transfers, plus IEEPA→Section 122 tariffs on Chinese importsmedium
Edgewise relies on third parties (CMOs/CROs) for its clinical supply chain and is exposed to escalating U.S. restrictions on China-linked contractors: the FDA has increased scrutiny of foreign drug-manufacturing facilities and contractors based in China, especially the transfer of biological materials, genetic data and sensitive American-patient data to parties in China, and a DOJ final rule (effective April 2025) limits/prohibits certain sensitive-personal-data transfers to China-linked partners. On trade, the U.S. imposed 10%–145% IEEPA tariffs on Chinese imports (since Feb 2025), which were rescinded Feb 24, 2026 after a Supreme Court ruling, only for the government to announce a new 15% 'temporary import surcharge' under Section 122 — all of which could disrupt its current or future China-linked third-party arrangements. A specific China supply-chain/data/trade-policy exposure.
“increased its scrutiny of foreign drug manufacturing facilities and other contractors based in China, especially with respect to the transfer of biological materials, genetic data, and other sensitive data of American patients to parties located in China.”
- IRA Medicare drug-price negotiation + inflation rebates — federal price-setting for high-priced single-source Medicare drugslow
Ahead of any commercialization, Edgewise flags the Inflation Reduction Act's prescription-drug provisions: the federal government can negotiate a 'maximum fair price' for certain high-priced single-source Medicare drugs, with penalties and excise tax for non-compliance, and inflation rebates apply to Medicare Part B/D drugs whose prices rise faster than inflation. For its muscle-disease candidates (sevasemten, EDG-7500), this is a future pricing/reimbursement exposure on the U.S. commercial opportunity, though orphan/rare-disease carve-outs may temper the negotiation impact. A specific but pre-commercial drug-pricing policy exposure.
“allowing the federal government to negotiate a maximum fair price for certain high-priced single source Medicare drugs”
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch